Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Gross Profit Growth Under PressureDecelerating
Percentile Rank41
5Y CAGR-7.0%
Year-over-Year Change
Year-over-year gross profit growth rate
5Y CAGR
-7.0%/yr
Long-term compound
Percentile
P41
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.74% |
| Q3 2025 | 4.08% |
| Q2 2025 | 6.23% |
| Q1 2025 | -3.27% |
| Q4 2024 | 4.59% |
| Q3 2024 | 4.64% |
| Q2 2024 | -3.02% |
| Q1 2024 | 9.07% |
| Q4 2023 | -0.70% |
| Q3 2023 | -0.91% |
| Q2 2023 | 3.64% |
| Q1 2023 | 4.38% |
| Q4 2022 | -1.25% |
| Q3 2022 | 5.71% |
| Q2 2022 | 4.47% |
| Q1 2022 | 1.45% |
| Q4 2021 | 4.44% |
| Q3 2021 | 11.64% |
| Q2 2021 | 2.18% |
| Q1 2021 | 7.53% |
| Q4 2020 | 5.37% |
| Q3 2020 | 0.90% |
| Q2 2020 | -0.93% |
| Q1 2020 | 10.12% |
| Q4 2019 | 50.17% |
| Q3 2019 | 1.53% |
| Q2 2019 | 5.53% |
| Q1 2019 | 2.08% |
| Q4 2018 | 11.07% |
| Q3 2018 | 3.94% |
| Q2 2018 | 13.81% |
| Q1 2018 | 0.28% |
| Q4 2017 | 12.33% |
| Q3 2017 | 6.84% |
| Q2 2017 | -29.17% |
| Q1 2017 | 67.68% |
| Q4 2016 | 10.71% |
| Q3 2016 | -6.90% |
| Q2 2016 | 11.20% |
| Q1 2016 | -1.72% |